Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review
- PMID: 31153145
- DOI: 10.3171/2019.3.FOCUS1967
Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review
Abstract
OBJECTIVEAdjuvant radiotherapy has become a common addition to the management of high-grade meningiomas, as immediate treatment with radiation following resection has been associated with significantly improved outcomes. Recent investigations into particle therapy have expanded into the management of high-risk meningiomas. Here, the authors systematically review studies on the efficacy and utility of particle-based radiotherapy in the management of high-grade meningioma.METHODSA literature search was developed by first defining the population, intervention, comparison, outcomes, and study design (PICOS). A search strategy was designed for each of three electronic databases: PubMed, Embase, and Scopus. Data extraction was conducted in accordance with the PRISMA guidelines. Outcomes of interest included local disease control, overall survival, and toxicity, which were compared with historical data on photon-based therapies.RESULTSEleven retrospective studies including 240 patients with atypical (WHO grade II) and anaplastic (WHO grade III) meningioma undergoing particle radiation therapy were identified. Five of the 11 studies included in this systematic review focused specifically on WHO grade II and III meningiomas; the others also included WHO grade I meningioma. Across all of the studies, the median follow-up ranged from 6 to 145 months. Local control rates for high-grade meningiomas ranged from 46.7% to 86% by the last follow-up or at 5 years. Overall survival rates ranged from 0% to 100% with better prognoses for atypical than for malignant meningiomas. Radiation necrosis was the most common adverse effect of treatment, occurring in 3.9% of specified cases.CONCLUSIONSDespite the lack of randomized prospective trials, this review of existing retrospective studies suggests that particle therapy, whether an adjuvant or a stand-alone treatment, confers survival benefit with a relatively low risk for severe treatment-derived toxicity compared to standard photon-based therapy. However, additional controlled studies are needed.
Keywords: CNS = central nervous system; IMPT = intensity-modulated proton therapy; OCEBM = Oxford Centre for Evidence-based Medicine; PICOS = population, intervention, comparison, outcomes, and study design; SRS = stereotactic radiosurgery; WHO = World Health Organization; atypical; malignant; meningioma; particle radiotherapy.
Similar articles
-
Major complications from radiotherapy following treatment for atypical meningiomas.Neurosurg Focus. 2019 Jun 1;46(6):E5. doi: 10.3171/2019.3.FOCUS1930. Neurosurg Focus. 2019. PMID: 31153147
-
Determining the role of adjuvant radiotherapy in the management of meningioma: a Surveillance, Epidemiology, and End Results analysis.Neurosurg Focus. 2019 Jun 1;46(6):E3. doi: 10.3171/2019.3.FOCUS1971. Neurosurg Focus. 2019. PMID: 31153148
-
Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy.J Neurooncol. 2000 Jun;48(2):151-60. doi: 10.1023/a:1006434124794. J Neurooncol. 2000. PMID: 11083080
-
Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.J Neurooncol. 2021 Apr;152(2):205-216. doi: 10.1007/s11060-020-03674-7. Epub 2021 Feb 26. J Neurooncol. 2021. PMID: 33635510 Review.
-
Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis.Neurosurg Focus. 2019 Jun 1;46(6):E2. doi: 10.3171/2019.3.FOCUS1970. Neurosurg Focus. 2019. PMID: 31153149
Cited by
-
Stereotactic Radiosurgery and Stereotactic Radiotherapy for Malignant Skull Base Tumors.Cureus. 2020 Jun 1;12(6):e8401. doi: 10.7759/cureus.8401. Cureus. 2020. PMID: 32637280 Free PMC article. Review.
-
Clinical Management of Supratentorial Non-Skull Base Meningiomas.Cancers (Basel). 2022 Nov 29;14(23):5887. doi: 10.3390/cancers14235887. Cancers (Basel). 2022. PMID: 36497370 Free PMC article. Review.
-
Seizures in brain tumors: pathogenesis, risk factors and management (Review).Int J Mol Med. 2025 May;55(5):82. doi: 10.3892/ijmm.2025.5523. Epub 2025 Mar 21. Int J Mol Med. 2025. PMID: 40116082 Free PMC article. Review.
-
Tumor Location Impacts the Development of Radiation Necrosis in Benign Intracranial Tumors.Cancers (Basel). 2023 Sep 28;15(19):4760. doi: 10.3390/cancers15194760. Cancers (Basel). 2023. PMID: 37835452 Free PMC article.
-
An interpretable radiomics model to select patients for radiotherapy after surgery for WHO grade 2 meningiomas.Radiat Oncol. 2022 Aug 22;17(1):147. doi: 10.1186/s13014-022-02090-7. Radiat Oncol. 2022. PMID: 35996160 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources